Hearts and Minds but no ratings

HM1 CIO, Rory Lucas recently spoke with the Financial Standard about our 12-month performance and the challenges in receiving ratings from the major research houses.

Ally Selby

Hearts and Minds but no ratings

July 21, 2020
HM1 CIO, Rory Lucas recently spoke with the Financial Standard about our 12-month performance and the challenges in receiving ratings from the major research houses.
Read Transcript

Listed impact investment vehicle Hearts and Minds Investments has returned more than 26% on a 12-month basis, while also donating $4.1 million to medical research. Yet, the fund has faced major roadblocks when it comes to receiving a rating.

The investment company offers shareholders the opportunity to benefit from the highest conviction ideas from prominent fund managers on a pro bono basis, including Caledonia Investments, Cooper Investors, Magellan Financial Group, Paradice Investment Management, Regal Funds Management and TDM Growth Partners.

It seems to be working; since its listing on the ASX in November 2018 the fund has returned 51.3%. Over the past six months alone it has returned 15.9%. In comparison, the MSCI World Net Total Return Index has returned 18.2% and -3.8% over the same periods.

Hearts and Minds also provides significant support to some of the country's leading medical re-search organisations, with 1.5% of its net tangible assets donated to beneficiaries such as the Victor Chang Cardiac Research Institute, the Black Dog Institute, the Charlie Teo Foundation and West-mead Children's Hospital.

However, since its IPO launch the investment company has seen little growth in awareness.

Perhaps, this can be chalked up to advisers only being able to recommend financial products that are on their licensee's approved product list. These products often require a rating from an agency such as Zenith, Morningstar or Lonsec, as well as a three year track record.

Independent research house Zenith, in particular, cannot rate the listed investment company, as its founder is also Hearts and Minds' Investment Committee Chair; a clear conflict of interest.

"I've got a little bit of a bugbear that to get on an approved list for financial advisers you've got to have particular reviews done of you," Hearts and Minds Investments chief investment officer Rory Lucas told Financial Standard.

"When we spoke to some of these ratings agencies, we said 'Look, we don't have a three-year track record, but Caledonia do, Magellan do, Paradice do, and we've got their best ideas' - but they struggled to look at it like that.

"Perhaps it's just a square peg in a round hole and we just have to wait."

Ratings agencies are not charities; they will either charge investment funds fees in return for a rating (often upwards of $50,000), charge licensing fees to use their logo in marketing collateral, or charge fees for funds to be featured in their industry database.

Hearts and Minds do not want to fork out for a rating, Lucas said, as he believes this money would be better spent by the company's beneficiaries.

Another ratings roadblock faced by the investment company is that its construction does not meet the typical portfolio "mould".

While 65% of the portfolio features the best ideas from prominent fund managers, the remaining 35% of the portfolio is made up of Australian and global stock picks from "conference" managers.

Every year, this portion of the portfolio is replaced by eligible long recommendations from the next Sohn Hearts and Minds Investment Leaders Conference.

"Because of this, it's not a replicable portfolio; so a lot of the research houses struggle to see that it has a long-term track record because it's not a fund that has been around for long enough and its fundamental investment construction sits outside their usual cookie cutter framework," Lucas said.

"It doesn't fit into the current mould; it's sort of an outlier when it comes to how they review funds, so that has been a challenge for us."

Even so, the average stock recommended during the conference will rally 50% within 12 months, he said.

"But it is difficult to communicate that to ratings houses," Lucas said.

"We are now putting together a list of financial planners just to go and talk to them about it; just to say, this is what we do, this is how it works, this is how the portfolio is constructed, this is how it has performed so far."

Otherwise it's just a waiting game, he said.

Hearts and Minds does have one rating from Independent Investment Research. It was assigned a "recommended plus" rating pre-IPO in 2018 as well as the subsequent year.

 

 

This article was first published on Financial Standard here.

Licensed by Copyright Agency. You must not copy this work without permission.

Listed impact investment vehicle Hearts and Minds Investments has returned more than 26% on a 12-month basis, while also donating $4.1 million to medical research. Yet, the fund has faced major roadblocks when it comes to receiving a rating.

The investment company offers shareholders the opportunity to benefit from the highest conviction ideas from prominent fund managers on a pro bono basis, including Caledonia Investments, Cooper Investors, Magellan Financial Group, Paradice Investment Management, Regal Funds Management and TDM Growth Partners.

It seems to be working; since its listing on the ASX in November 2018 the fund has returned 51.3%. Over the past six months alone it has returned 15.9%. In comparison, the MSCI World Net Total Return Index has returned 18.2% and -3.8% over the same periods.

Hearts and Minds also provides significant support to some of the country's leading medical re-search organisations, with 1.5% of its net tangible assets donated to beneficiaries such as the Victor Chang Cardiac Research Institute, the Black Dog Institute, the Charlie Teo Foundation and West-mead Children's Hospital.

However, since its IPO launch the investment company has seen little growth in awareness.

Perhaps, this can be chalked up to advisers only being able to recommend financial products that are on their licensee's approved product list. These products often require a rating from an agency such as Zenith, Morningstar or Lonsec, as well as a three year track record.

Independent research house Zenith, in particular, cannot rate the listed investment company, as its founder is also Hearts and Minds' Investment Committee Chair; a clear conflict of interest.

"I've got a little bit of a bugbear that to get on an approved list for financial advisers you've got to have particular reviews done of you," Hearts and Minds Investments chief investment officer Rory Lucas told Financial Standard.

"When we spoke to some of these ratings agencies, we said 'Look, we don't have a three-year track record, but Caledonia do, Magellan do, Paradice do, and we've got their best ideas' - but they struggled to look at it like that.

"Perhaps it's just a square peg in a round hole and we just have to wait."

Ratings agencies are not charities; they will either charge investment funds fees in return for a rating (often upwards of $50,000), charge licensing fees to use their logo in marketing collateral, or charge fees for funds to be featured in their industry database.

Hearts and Minds do not want to fork out for a rating, Lucas said, as he believes this money would be better spent by the company's beneficiaries.

Another ratings roadblock faced by the investment company is that its construction does not meet the typical portfolio "mould".

While 65% of the portfolio features the best ideas from prominent fund managers, the remaining 35% of the portfolio is made up of Australian and global stock picks from "conference" managers.

Every year, this portion of the portfolio is replaced by eligible long recommendations from the next Sohn Hearts and Minds Investment Leaders Conference.

"Because of this, it's not a replicable portfolio; so a lot of the research houses struggle to see that it has a long-term track record because it's not a fund that has been around for long enough and its fundamental investment construction sits outside their usual cookie cutter framework," Lucas said.

"It doesn't fit into the current mould; it's sort of an outlier when it comes to how they review funds, so that has been a challenge for us."

Even so, the average stock recommended during the conference will rally 50% within 12 months, he said.

"But it is difficult to communicate that to ratings houses," Lucas said.

"We are now putting together a list of financial planners just to go and talk to them about it; just to say, this is what we do, this is how it works, this is how the portfolio is constructed, this is how it has performed so far."

Otherwise it's just a waiting game, he said.

Hearts and Minds does have one rating from Independent Investment Research. It was assigned a "recommended plus" rating pre-IPO in 2018 as well as the subsequent year.

 

 

This article was first published on Financial Standard here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by Financial Standard, published on Jul 21, 2020. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
May 19, 2025

HM1 Leadership Restructure

The Board has announced the restructure of its leadership, transitioning from a full-time CEO role to a more streamlined model. As a result, Brett Jollie will step down as CEO and Richard Howes will be appointed to a new part-time role of Managing Director.

Read More
June 12, 2025

Coeur Mining – a high-conviction precious metals re-rating story

Coeur Mining provides access to precious metals production in politically stable jurisdictions, with potential for operational and valuation upside.

Read More
March 10, 2025

Reporting Season Insights: HM1 Core Portfolio Holdings

We spoke to our dedicated fund managers for an update on some of our major portfolio holdings following reporting season.

Read More
February 20, 2025

Significant increase in profit and increased fully franked dividend

We're pleased to declare an increased half-year fully franked dividend of 8.0 cents per share payable in April 2025.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
December 5, 2024

HM1 CEO Succession

Hearts and Minds Investments Limited advises that Paul Rayson intends to retire from the position of Chief Executive Officer, effective 19 February 2025.

Read More
Chris Cuffe, chairman of Hearts and Minds Investments, with chief investment officer Charlie Lanchester. Picture: John FederChris Cuffe, chairman of Hearts and Minds Investments, with chief investment officer Charlie Lanchester. Picture: John FederChris Cuffe, chairman of Hearts and Minds Investments, with chief investment officer Charlie Lanchester. Picture: John FederChris Cuffe, chairman of Hearts and Minds Investments, with chief investment officer Charlie Lanchester. Picture: John Feder
November 14, 2024

Sohn Hearts & Minds Investments fund targets $1.5bn valuation

‍Hearts & Minds Investments chair Chris Cuffe is hoping for HM1 to grow to more than $1.5bn in the next five years.

Read More
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lancaster sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 6, 2024

Exploring HM1 Top Stocks: Key Insights from Reporting Season

We have just come to the end of reporting season and the fund managers of our major portfolio holdings gave us their insights into the latest results of our key holdings.

Read More
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
March 7, 2024

Exploring HM1 Stocks: Key Insights from Reporting Season

We asked our fund managers for an update on how some of our key positions are performing off the back of the reporting season. Overall, it was a good period for the fund with some good moves to the upside.

Read More
February 6, 2024

Stock Story: ResMed

This month we take a deep dive into ResMed - one of the conference stocks within the fund that was astutely picked by Chris Kourtis of Ellerston Capital.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lancaster sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.